source
- AbbVie faces questions about Skyrizi competition from J&JThreats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of the…Endpoints · 3mo ago↗ source
- FDA, AstraZeneca prep for oncology adcommThe FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the focus of the discussion. Details about the meeting of the ...Endpoints · 3mo ago↗ source
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.BioPharma Dive · 3mo ago